BCAL clears validation hurdle for broader breast cancer test launch

• BREASTESTplus 2 validated with 80.3% sensitivity and 48.5% specificity in early-stage breast cancer study
• November launch targeted across Sydney, Melbourne and Brisbane, subject to accreditation and operational readiness
• Avantect Multicancer introduced at selected sites, with national rollout preparations through Sonic Healthcare and Healius
• Quarterly revenue of $30,800 from 29 tests, against $1.895 million in net operating cash outflows